Literature DB >> 27470605

Effect of age and body weight on toxicity and survival in pediatric acute myeloid leukemia: results from NOPHO-AML 2004.

Ditte J A Løhmann1, Jonas Abrahamsson2, Shau-Yin Ha3, Ólafur G Jónsson4, Minna Koskenvuo5, Birgitte Lausen6, Josefine Palle7, Bernward Zeller8, Henrik Hasle9.   

Abstract

Treatment for pediatric acute myeloid leukemia is very toxic and the association between outcome and age and Body Mass Index is unclear. We investigated effect of age and Body Mass Index on toxicity and survival in pediatric acute myeloid leukemia. We studied all patients who completed first induction course of NOPHO-AML 2004 (n=318). Toxicity following induction and consolidation courses (n=6) was analyzed. The probabilities of toxicity and death were determined using time-to-event analyses with Cox multivariate proportional hazard regression for comparative analyses. Age 10-17 years was associated with sepsis with hypotension [hazard ratio 2.3 (95% confidence interval 1.1-4.6)]. Being overweight (>1 standard deviation) was associated with requiring supplemental oxygen [1.9 (1.0-3.5)]. The 5-year event-free and overall survival were 47% and 71%. Children aged 10-17 years showed a trend for inferior 5-year overall survival compared to children aged 2-9 (64% vs. 76%; P=0.07). Infants showed a trend for superior 5-year event-free survival (66% vs. 43%; P=0.06). Overweight children aged 10-17 years showed a trend for superior survival [5-year event-free survival 59% vs. 40% (P=0.09) and 5-year overall survival 78% vs. 56% (P=0.06)] compared to healthy weight children aged 10-17 years. In conclusion, children aged 10-17 years and overweight children had a higher risk of grade 3-4 toxicity. Children aged 10-17 years showed inferior survival, but, unexpectedly, in this age group overweight children tended to have increased survival. This suggests different pharmacokinetics of chemotherapeutic drugs in adolescents and warrants further studies. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27470605      PMCID: PMC5394883          DOI: 10.3324/haematol.2016.146175

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  40 in total

1.  Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

Authors:  Jeffrey E Rubnitz; Hiroto Inaba; Gary Dahl; Raul C Ribeiro; W Paul Bowman; Jeffrey Taub; Stanley Pounds; Bassem I Razzouk; Norman J Lacayo; Xueyuan Cao; Soheil Meshinchi; Barbara Degar; Gladstone Airewele; Susana C Raimondi; Mihaela Onciu; Elaine Coustan-Smith; James R Downing; Wing Leung; Ching-Hon Pui; Dario Campana
Journal:  Lancet Oncol       Date:  2010-05-05       Impact factor: 41.316

2.  Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions.

Authors:  Bassem I Razzouk; Elihu Estey; Stanley Pounds; Shelly Lensing; Sherry Pierce; Mark Brandt; Jeffrey E Rubnitz; Raul C Ribeiro; Michael Rytting; Ching-Hon Pui; Hagop Kantarjian; Sima Jeha
Journal:  Cancer       Date:  2006-06-01       Impact factor: 6.860

3.  Effect of body mass index on the outcome of children with acute myeloid leukemia.

Authors:  Hiroto Inaba; Harriet C Surprise; Stanley Pounds; Xueyuan Cao; Scott C Howard; Karen Ringwald-Smith; Jassada Buaboonnam; Gary Dahl; W Paul Bowman; Jeffrey W Taub; Dario Campana; Ching-Hon Pui; Raul C Ribeiro; Jeffrey E Rubnitz
Journal:  Cancer       Date:  2012-05-30       Impact factor: 6.860

4.  Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia.

Authors:  Lillian Sung; Beverly J Lange; Robert B Gerbing; Todd A Alonzo; James Feusner
Journal:  Blood       Date:  2007-07-27       Impact factor: 22.113

5.  Life-threatening and fatal infections in children with acute myeloid leukemia: a report from the Children's Oncology Group.

Authors:  Lillian Sung; Allen Buxton; Alan Gamis; William G Woods; Todd A Alonzo
Journal:  J Pediatr Hematol Oncol       Date:  2012-01       Impact factor: 1.289

6.  International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia.

Authors:  Thomas Lehrnbecher; Marie-Chantal Ethier; Theoklis Zaoutis; Ursula Creutzig; Alan Gamis; Dirk Reinhardt; Richard Aplenc; Lillian Sung
Journal:  Br J Haematol       Date:  2009-08-05       Impact factor: 6.998

Review 7.  The toxicity of cytarabine.

Authors:  J Stentoft
Journal:  Drug Saf       Date:  1990 Jan-Feb       Impact factor: 5.606

8.  NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias.

Authors:  A P Periclou; V I Avramis
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

9.  Treatment outcome in older patients with childhood acute myeloid leukemia.

Authors:  Jeffrey E Rubnitz; Stanley Pounds; Xueyuan Cao; Laura Jenkins; Gary Dahl; W Paul Bowman; Jeffrey W Taub; Ching-Hon Pui; Raul C Ribeiro; Dario Campana; Hiroto Inaba
Journal:  Cancer       Date:  2012-06-06       Impact factor: 6.860

10.  Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children's Oncology Group.

Authors:  Jason Canner; Todd A Alonzo; Janet Franklin; David R Freyer; Alan Gamis; Robert B Gerbing; Beverly J Lange; Soheil Meshinchi; William G Woods; John Perentesis; John Horan
Journal:  Cancer       Date:  2013-09-19       Impact factor: 6.860

View more
  13 in total

1.  Cost-effectiveness of levofloxacin prophylaxis against bacterial infection in pediatric patients with acute myeloid leukemia.

Authors:  Meghan McCormick; Erika Friehling; Ramasubramanian Kalpatthi; Nalyn Siripong; Kenneth Smith
Journal:  Pediatr Blood Cancer       Date:  2020-07-25       Impact factor: 3.167

2.  Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Authors:  Tamara P Miller; Yimei Li; Marko Kavcic; Kelly D Getz; Yuan-Shun V Huang; Lillian Sung; Todd A Alonzo; Robert Gerbing; Marla H Daves; Terzah M Horton; Michael A Pulsipher; Jessica Pollard; Rochelle Bagatell; Alix E Seif; Brian T Fisher; Selina Luger; Alan S Gamis; Peter C Adamson; Richard Aplenc
Journal:  Haematologica       Date:  2017-06-22       Impact factor: 9.941

3.  Birthweight and all-cause mortality after childhood and adolescent leukemia: a cohort of children with leukemia from Denmark, Norway, Sweden, and Washington State.

Authors:  Anne Gulbech Ording; Lotte Brix Christensen; Tone Bjørge; David R Doody; Anders Ekbom; Ingrid Glimelius; Tom Grotmol; Gunnar Larfors; Beth A Mueller; Karin E Smedby; Steinar Tretli; Rebecca Troisi; Henrik Toft Sørensen
Journal:  Acta Oncol       Date:  2020-03-14       Impact factor: 4.089

Review 4.  A Review on the Impact of Body Mass Index on Outcomes in Pediatric Leukemia.

Authors:  Annalisa Paviglianiti
Journal:  J Blood Med       Date:  2020-06-18

5.  Body Mass Index at Pediatric Leukemia Diagnosis and the Risks of Relapse and Mortality: Findings from a Single Institution and Meta-analysis.

Authors:  Ashleigh M Saenz; Stacie Stapleton; Raquel G Hernandez; Greg A Hale; Neil A Goldenberg; Skai Schwartz; Ernest K Amankwah
Journal:  J Obes       Date:  2018-11-01

6.  Associations between pretherapeutic body mass index, outcome, and cytogenetic abnormalities in pediatric acute myeloid leukemia.

Authors:  Ditte J A Løhmann; Peter H Asdahl; Jonas Abrahamsson; Shau-Yin Ha; Ólafur G Jónsson; Gertjan J L Kaspers; Minna Koskenvuo; Birgitte Lausen; Barbara De Moerloose; Josefine Palle; Bernward Zeller; Lillian Sung; Henrik Hasle
Journal:  Cancer Med       Date:  2019-09-18       Impact factor: 4.452

7.  Depicting the genetic architecture of pediatric cancers through an integrative gene network approach.

Authors:  Yuna Blum; Marie de Tayrac; Clara Savary; Artem Kim; Alexandra Lespagnol; Virginie Gandemer; Isabelle Pellier; Charlotte Andrieu; Gilles Pagès; Marie-Dominique Galibert
Journal:  Sci Rep       Date:  2020-01-27       Impact factor: 4.379

Review 8.  Nutritional Status of Pediatric Cancer Patients at Diagnosis and Correlations with Treatment, Clinical Outcome and the Long-Term Growth and Health of Survivors.

Authors:  Vassiliki Diakatou; Tonia Vassilakou
Journal:  Children (Basel)       Date:  2020-11-07

9.  Long-term health outcomes in survivors of childhood AML treated with allogeneic HSCT: a NOPHO-AML Study.

Authors:  Mari Wilhelmsson; Heidi Glosli; Marianne Ifversen; Jonas Abrahamsson; Jacek Winiarski; Kirsi Jahnukainen; Henrik Hasle
Journal:  Bone Marrow Transplant       Date:  2018-09-21       Impact factor: 5.483

10.  Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group.

Authors:  Kelly D Getz; Lillian Sung; Bonnie Ky; Robert B Gerbing; Kasey J Leger; Allison Barz Leahy; Leah Sack; William G Woods; Todd Alonzo; Alan Gamis; Richard Aplenc
Journal:  J Clin Oncol       Date:  2018-10-31       Impact factor: 50.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.